KENNETH B PUGAR
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- CENTERVILLE, OH
- NPI
- 1528060399
- Received
- $596,194 in 1,516 records, 2019 to 2025 ($581,669 general, $14,525 research); ownership interests with $266,513 invested
- As principal investigator
- $1,325,404 of research payments to others in 303 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 181 | $88,688 |
| 2024 | General payment | 203 | $87,150 |
| 2023 | General payment | 184 | $55,792 |
| 2022 | General payment | 238 | $81,435 |
| 2021 | General payment | 285 | $133,053 |
| 2020 | General payment | 187 | $56,357 |
| 2020 | Research payment | 2 | $5,525 |
| 2019 | General payment | 230 | $79,192 |
| 2019 | Ownership or investment interest | 2 | $266,513 |
| 2019 | Research payment | 4 | $9,000 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 154 | $425,785 |
| Ownership or investment interest | 2 | $266,513 |
| Travel and Lodging | 97 | $54,438 |
| Consulting Fee | 32 | $49,763 |
| Food and Beverage | 1,200 | $31,498 |
| Compensation for serving as faculty or as a speaker for a medical education program | 14 | $19,597 |
| Research payment | 6 | $14,525 |
| Education | 11 | $587 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | EMD Serono, Inc. | $690 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-22 | Eisai Inc. | $110 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-12-22 | Neurelis, Inc. | $18 | Food and Beverage | In-kind items and services | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-12-19 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-19 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-12-19 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-12-15 | Axsome Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-12-11 | Grifols USA, LLC | $24 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2025 | |
| 2025-12-01 | EMD Serono, Inc. | $3,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-26 | Eisai Inc. | $1,300 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-11-20 | MDD US Operations, LLC | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-20 | MDD US Operations, LLC | $2 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-19 | Biogen, Inc. | $16 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-11-17 | Amneal Pharmaceuticals LLC | $23 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-11-13 | EMD Serono, Inc. | $127 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-11 | MDD US Operations, LLC | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-06 | EMD Serono, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | EMD Serono, Inc. | $73 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-04 | Amneal Pharmaceuticals LLC | $25 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-11-04 | MDD US Operations, LLC | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-03 | ACADIA Pharmaceuticals Inc | $24 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-10-30 | Lilly USA, LLC | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-10-30 | Lilly USA, LLC | $1,325 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-10-30 | UCB, Inc. | $21 | Food and Beverage | In-kind items and services | Nayzilam Drug, Neurology | 2025 | |
| 2025-10-30 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-29 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-10-29 | Eisai Inc. | $17 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-10-27 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-10-24 | Lilly USA, LLC | $801 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | Lilly USA, LLC | $1,312 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-10-22 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-10-22 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-10-16 | Lilly USA, LLC | $121 | Food and Beverage | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-10-16 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Amneal Pharmaceuticals LLC | $26 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-10-08 | Alexion Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-10-06 | Eisai Inc. | $1,040 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-09-30 | Axsome Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-09-29 | ARGENX US, INC. | $26 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-09-23 | Lilly USA, LLC | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-09-23 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-09-22 | Vanda Pharmaceuticals Inc. | $39 | Food and Beverage | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-09-19 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-11 | Grifols USA, LLC | $17 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2025 | |
| 2025-09-10 | EMD Serono, Inc. | $84 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-09 | Biogen, Inc. | $16 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-09-08 | Lilly USA, LLC | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-09-08 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-09-05 | Eisai Inc. | $15 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-09-02 | EMD Serono, Inc. | $6,555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-02 | EMD Serono, Inc. | $3,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-29 | Eisai Inc. | $30 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-27 | JAZZ PHARMACEUTICALS INC. | $24 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-08-26 | Eisai Inc. | $520 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-08-20 | UCB, Inc. | $28 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-08-18 | ARGENX US, INC. | $28 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-08-18 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-12 | EMD Serono, Inc. | $517 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-05 | MDD US Operations, LLC | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-05 | MDD US Operations, LLC | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-04 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-07-30 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-07-24 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-07-22 | Teva Pharmaceuticals USA, Inc. | $91 | Education | In-kind items and services | 2025 | ||
| 2025-07-16 | EMD Serono, Inc. | $3,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-14 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2025 | |
| 2025-07-10 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-07-09 | Biogen, Inc. | $15 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-02 | Axsome Therapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-07-01 | EMD Serono, Inc. | $6,555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-01 | MDD US Operations, LLC | $8 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Apokyn Drug, APOMORPHINE HYDROCHLORIDE | 2025 | |
| 2025-06-30 | Eisai Inc. | $22 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-06-27 | Eisai Inc. | $1,121 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-06-24 | Eisai Inc. | $1,755 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-06-24 | Eisai Inc. | $1,462 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-06-24 | Eisai Inc. | $121 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-06-23 | EMD Serono, Inc. | $22 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-06-21 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-06-19 | EMD Serono, Inc. | $50 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-17 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2025 | |
| 2025-06-14 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-06-13 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-12 | Merz Pharmaceuticals, LLC | $22 | Food and Beverage | In-kind items and services | Xeomin Biological, Musculoskeletal | 2025 | |
| 2025-06-11 | Alexion Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-06-11 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-09 | EMD Serono, Inc. | $1,341 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-09 | EMD Serono, Inc. | $150 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-09 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-04 | MDD US Operations, LLC | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-03 | MDD US Operations, LLC | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-02 | Lilly USA, LLC | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-06-02 | Lilly USA, LLC | $1,325 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-29 | UCB, Inc. | $24 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-05-28 | Lilly USA, LLC | $915 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-28 | Lilly USA, LLC | $54 | Food and Beverage | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-28 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-05-28 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-05-23 | EMD Serono, Inc. | $10,005 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-05-23 | Lilly USA, LLC | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-23 | Lilly USA, LLC | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-21 | SK Life Science, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-21 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-05-20 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-05-14 | Lilly USA, LLC | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-14 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-13 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-05-13 | MDD US Operations, LLC | $7 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-05-12 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-05-12 | MDD US Operations, LLC | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-09 | Eisai Inc. | $182 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-05-09 | Eisai Inc. | $110 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-05-07 | Lilly USA, LLC | $124 | Food and Beverage | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-05-07 | Amneal Pharmaceuticals LLC | $20 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-05-05 | Biogen, Inc. | $18 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-05-03 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-03 | Lilly USA, LLC | $6 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-05-01 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-30 | Eisai Inc. | $1,462 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-30 | Eisai Inc. | $585 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-30 | Eisai Inc. | $67 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-30 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-04-28 | Amneal Pharmaceuticals LLC | $20 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-04-23 | SK Life Science, Inc. | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-23 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-21 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-04-16 | Eisai Inc. | $29 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-04-05 | EMD Serono, Inc. | $90 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-05 | EMD Serono, Inc. | $75 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-05 | EMD Serono, Inc. | $31 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-04 | EMD Serono, Inc. | $319 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-04 | EMD Serono, Inc. | $184 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-01 | ACADIA Pharmaceuticals Inc | $29 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-03-31 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-26 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-03-25 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-03-24 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-17 | MDD US Operations, LLC | $23 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-03-14 | EMD Serono, Inc. | $6,555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-03-14 | EMD Serono, Inc. | $44 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-13 | EMD Serono, Inc. | $1,707 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-03-13 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-03-13 | EMD Serono, Inc. | $47 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-03-12 | UCB, Inc. | $66 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-03-12 | UCB, Inc. | $58 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-03-11 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-03-11 | MDD US Operations, LLC | $5 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-03-07 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-03-05 | EMD Serono, Inc. | $63 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-05 | MDD US Operations, LLC | $18 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-03-04 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-03-03 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-02-21 | PFIZER INC. | $29 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-02-20 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-02-19 | EMD Serono, Inc. | $109 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-19 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-18 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-02-17 | EMD Serono, Inc. | $105 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-17 | UCB, Inc. | $14 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2025 | |
| 2025-02-11 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-02-10 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-01-30 | EMD Serono, Inc. | $345 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-01-30 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-01-29 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-01-28 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-01-24 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-01-22 | Eisai Inc. | $1,462 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-22 | Eisai Inc. | $585 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-22 | Eisai Inc. | $120 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-22 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-01-22 | Takeda Pharmaceuticals U.S.A., Inc. | $13 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-01-17 | TG Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-01-16 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-15 | UCB, Inc. | $18 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-01-14 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-01-09 | SK Life Science, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-03 | EMD Serono, Inc. | $3,273 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2024-12-30 | Grifols USA, LLC | $18 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2024 | |
| 2024-12-03 | MDD US Operations, LLC | $14 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2024 | |
| 2024-12-03 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-11-27 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2024 | |
| 2024-11-20 | Eisai Inc. | $33 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-11-19 | EMD Serono, Inc. | $3,273 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2024 | |
| 2024-11-18 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-15 | EMD Serono, Inc. | $62 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-11-12 | EMD Serono, Inc. | $27 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-11-10 | Biogen, Inc. | $18 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2024 | |
| 2024-11-08 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-11-07 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-11-03 | MDD US Operations, LLC | $19 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2024 | |
| 2024-11-03 | MDD US Operations, LLC | $5 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2024 | |
| 2024-10-31 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-10-30 | Axsome Therapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2024 | |
| 2024-10-30 | EMD Serono, Inc. | $9 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-10-29 | Eisai Inc. | $29 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-10-28 | Lilly USA, LLC | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KISUNLA Drug, Neuroscience | 2024 |
The latest 200 records of 1,516.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | GENZYME CORPORATION | Interspond Llc | $471 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-10-20 | GENZYME CORPORATION | Interspond Llc | $3,000 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-10-20 | GENZYME CORPORATION | Interspond Llc | $1,960 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-10-20 | GENZYME CORPORATION | Interspond Llc | $2,000 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-10-20 | GENZYME CORPORATION | Interspond Llc | $1,845 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-10-20 | GENZYME CORPORATION | Interspond Llc | $465 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-09-03 | GENZYME CORPORATION | Interspond Llc | $25,574 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-08-11 | GENZYME CORPORATION | Interspond Llc | $1,669 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-07-14 | GENZYME CORPORATION | Interspond Llc | $976 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-07-14 | GENZYME CORPORATION | Interspond Llc | $511 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-07-14 | GENZYME CORPORATION | Interspond Llc | $511 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-06-09 | GENZYME CORPORATION | Interspond Llc | $69,244 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-05-19 | GENZYME CORPORATION | Interspond Llc | $7,500 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2025 |
| 2025-05-12 | GENZYME CORPORATION | Interspond Llc | $7,500 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2025 |
| 2025-04-02 | GENZYME CORPORATION | Interspond Llc | $1,029 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-03-24 | GENZYME CORPORATION | Interspond Llc | $3,000 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-02-18 | GENZYME CORPORATION | Interspond Llc | $657 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-01-27 | GENZYME CORPORATION | Interspond Llc | $6,699 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2025 |
| 2025-01-24 | GENZYME CORPORATION | Interspond Llc | $790 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-01-16 | ABBVIE INC. | Interspond Llc | $175 | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | 2025 |
| 2024-12-16 | GENZYME CORPORATION | Interspond Llc | $750 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-12-16 | GENZYME CORPORATION | Interspond Llc | $1,012 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-12-12 | ABBVIE INC. | Interspond Llc | $6,550 | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | 2024 |
| 2024-12-09 | GENZYME CORPORATION | Interspond Llc | $4,416 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-12-09 | GENZYME CORPORATION | Interspond Llc | $1,116 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-12 | GENZYME CORPORATION | Interspond Llc | $1,104 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-04 | GENZYME CORPORATION | Interspond Llc | $17,634 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-04 | GENZYME CORPORATION | Interspond Llc | $18,426 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-04 | GENZYME CORPORATION | Interspond Llc | $832 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-04 | GENZYME CORPORATION | Interspond Llc | $1,209 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-10-28 | GENZYME CORPORATION | Interspond Llc | $1,255 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-10-15 | GENZYME CORPORATION | Interspond Llc | $6,931 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-10-15 | GENZYME CORPORATION | Interspond Llc | $71,158 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-08-26 | GENZYME CORPORATION | Interspond Llc | $63,950 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-08-05 | GENZYME CORPORATION | Interspond Llc | $519 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-07-22 | GENZYME CORPORATION | Interspond Llc | $21,625 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-07-15 | GENZYME CORPORATION | Interspond Llc | $1,763 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-07-02 | GENZYME CORPORATION | Interspond Llc | $290 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-06-04 | GENZYME CORPORATION | Interspond Llc | $4,731 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-06-04 | GENZYME CORPORATION | Interspond Llc | $562 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-04-22 | GENZYME CORPORATION | Interspond Llc | $7,097 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-03-25 | GENZYME CORPORATION | Interspond Llc | $5,337 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-03-04 | GENZYME CORPORATION | Interspond Llc | $736 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-02-26 | GENZYME CORPORATION | Interspond Llc | $31,751 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-02-20 | GENZYME CORPORATION | Interspond Llc | $513 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-02-05 | GENZYME CORPORATION | Interspond Llc | $668 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-02-05 | GENZYME CORPORATION | Interspond Llc | $772 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-01-22 | GENZYME CORPORATION | Interspond Llc | $27,907 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2023-12-18 | GENZYME CORPORATION | Interspond Llc | $2,274 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-12-11 | GENZYME CORPORATION | Interspond Llc | $663 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-11-20 | GENZYME CORPORATION | Interspond Llc | $11,449 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-30 | GENZYME CORPORATION | Interspond Llc | $19,122 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-09-18 | GENZYME CORPORATION | Interspond Llc | $14,515 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-28 | GENZYME CORPORATION | Interspond Llc | $322 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-14 | GENZYME CORPORATION | Interspond Llc | $19,414 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-02 | GENZYME CORPORATION | Interspond Llc | $6,882 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-24 | GENZYME CORPORATION | Interspond Llc | $13,488 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-17 | GENZYME CORPORATION | Interspond Llc | $740 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-05-25 | GENZYME CORPORATION | Interspond Llc | $925 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-05-25 | GENZYME CORPORATION | Interspond Llc | $15,999 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-04-24 | GENZYME CORPORATION | Interspond Llc | $1,278 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-04-24 | GENZYME CORPORATION | Interspond Llc | $28,152 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-04-04 | GENZYME CORPORATION | Interspond Llc | $355 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-04-04 | GENZYME CORPORATION | Interspond Llc | $1,454 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-03-27 | GENZYME CORPORATION | Interspond Llc | $597 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-03-20 | GENZYME CORPORATION | Interspond Llc | $11,724 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-03-20 | GENZYME CORPORATION | Interspond Llc | $916 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-02-27 | GENZYME CORPORATION | Interspond Llc | $2,000 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-02-27 | GENZYME CORPORATION | Interspond Llc | $16,581 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-02-06 | GENZYME CORPORATION | Interspond Llc | $1,000 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-02-06 | GENZYME CORPORATION | Interspond Llc | $27,641 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-01-30 | GENZYME CORPORATION | Interspond Llc | $22,884 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-01-11 | Biogen, Inc. | Dayton Center Of Neurological Disorders | $911 | A Prospective Real-World Observational Study Of Aducanumab In Patients With Alzheimers Disease: ICARE AD US | 2023 |
| 2022-12-05 | GENZYME CORPORATION | Interspond Llc | $655 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-12-05 | GENZYME CORPORATION | Interspond Llc | $3,000 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-12-05 | GENZYME CORPORATION | Interspond Llc | $43 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-11-02 | GENZYME CORPORATION | Interspond Llc | $6,090 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-10-11 | GENZYME CORPORATION | Interspond Llc | $58,650 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-10-11 | GENZYME CORPORATION | Interspond Llc | $1,517 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-10-04 | GENZYME CORPORATION | Interspond Llc | $37,097 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-09-26 | GENZYME CORPORATION | Interspond Llc | $35,974 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-09-12 | GENZYME CORPORATION | Interspond Llc | $12,420 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-09-06 | GENZYME CORPORATION | Interspond Llc | $14,863 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-09-06 | GENZYME CORPORATION | Interspond Llc | $463 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-07-18 | GENZYME CORPORATION | Interspond Llc | $1,200 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-07-05 | GENZYME CORPORATION | Interspond Llc | $505 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-06-28 | GENZYME CORPORATION | Interspond Llc | $25,098 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-06-15 | Eli Lilly and Company | Interspond Llc | $7,964 | A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US | 2022 |
| 2022-06-06 | GENZYME CORPORATION | Interspond Llc | $411 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-06-02 | GENZYME CORPORATION | Interspond Llc | $544 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-05-09 | GENZYME CORPORATION | Interspond Llc | $63,588 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-04-11 | GENZYME CORPORATION | Interspond Llc | $5,717 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-04-11 | GENZYME CORPORATION | Interspond Llc | $1,449 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-04-11 | GENZYME CORPORATION | Interspond Llc | $20,897 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-04-04 | GENZYME CORPORATION | Interspond Llc | $777 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-04-04 | GENZYME CORPORATION | Interspond Llc | $470 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-03-28 | GENZYME CORPORATION | Interspond Llc | $250 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-01-18 | Biogen, Inc. | Dayton Center Of Neurological Disorders | $9,540 | A Prospective Real-World Observational Study Of Aducanumab In Patients With Alzheimers Disease: ICARE AD US | 2022 |
| 2022-01-04 | GENZYME CORPORATION | Interspond Llc | $699 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
| 2022-01-04 | GENZYME CORPORATION | Interspond Llc | $1,367 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Centerville, OH, county Montgomery County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Centerville, OH | County Montgomery County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 25,205 | 536,096 | 11,810,293 |
| Population, 2020 census P1 | 24,240 | 537,309 | 11,799,448 |
| Median age B01002 | 46.4 | 38.8 | 39.7 |
| Under 18 B01001 | 19.3% | 22.2% | 22.0% |
| 65 and over B01001 | 29.0% | 18.6% | 18.3% |
| Households B11001 | 11,829 | 231,319 | 4,863,191 |
| Foreign born B05002 | 6.8% | 5.3% | 5.2% |
| Median household income B19013 | $85,492 | $66,139 | $71,389 |
| Median family income B19113 | $115,308 | $87,506 | $92,749 |
| Per capita income B19301 | $50,775 | $38,450 | $40,552 |
| Poverty rate B17001 | 8.6% | 15.0% | 13.3% |
| Unemployment rate B23025 | 3.4% | 5.7% | 4.8% |
| Civilian labor force B23025 | 12,634 | 269,810 | 5,994,779 |
| Mean commute (minutes) B08013 | 20.4 | 21.9 | 23.4 |
| Bachelor's degree or higher B15003 | 47.3% | 31.3% | 31.5% |
| Housing units B25001 | 12,143 | 252,843 | 5,292,391 |
| Owner-occupied B25003 | 67.0% | 62.5% | 67.2% |
| Renters B25003 | 33.0% | 37.5% | 32.8% |
| Median home value B25077 | $287,200 | $180,900 | $214,800 |
| Median gross rent B25064 | $1,270 | $1,026 | $1,034 |
| White, not Hispanic B03002 | 81.7% | 67.7% | 75.8% |
| Black B03002 | 6.2% | 20.4% | 12.0% |
| Hispanic or Latino B03002 | 5.7% | 4.2% | 4.8% |
| Asian B03002 | 2.2% | 2.2% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Centerville, OH.
Comments